Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biohaven Pharmaceutical Holding Ltd (BHVN)

Biohaven Pharmaceutical Holding Ltd (BHVN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,723,186
  • Shares Outstanding, K 65,401
  • Annual Sales, $ 63,630 K
  • Annual Income, $ -766,800 K
  • 60-Month Beta 1.03
  • Price/Sales 139.33
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BHVN with:

Options Overview Details

View History
  • Implied Volatility 62.85%
  • Historical Volatility 26.32%
  • IV Percentile 37%
  • IV Rank 23.87%
  • IV High 125.63% on 01/05/21
  • IV Low 43.16% on 05/28/21
  • Put/Call Vol Ratio 5.66
  • Today's Volume 599
  • Volume Avg (30-Day) 528
  • Put/Call OI Ratio 1.35
  • Today's Open Interest 2,840
  • Open Int (30-Day) 5,726

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -2.65
  • Number of Estimates 5
  • High Estimate -1.94
  • Low Estimate -3.20
  • Prior Year -3.27
  • Growth Rate Est. (year over year) +18.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
128.41 +3.48%
on 08/30/21
139.66 -4.85%
on 09/17/21
+2.70 (+2.07%)
since 08/27/21
3-Month
94.93 +39.98%
on 06/28/21
139.66 -4.85%
on 09/17/21
+34.52 (+35.10%)
since 06/25/21
52-Week
61.50 +116.07%
on 09/29/20
139.66 -4.85%
on 09/17/21
+70.19 (+111.96%)
since 09/25/20

Most Recent Stories

More News
Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) Program

/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced results from a focused analysis of a clinical trial of verdiperstat in multiple system atrophy (MSA).  Verdiperstat...

BHVN : 132.88 (-0.37%)
Biohaven Spotlights Nurtec® ODT (rimegepant), the only dual-therapy indicated for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Federation Joint Congress

/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 17 abstracts, including three late-breaking presentations and four oral presentations, will be shared at...

BHVN : 132.88 (-0.37%)
Why Is Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 21.7% Since Last Earnings Report?

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BHVN : 132.88 (-0.37%)
Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong

Biohaven's (BHVN) sole approved drug, Nurtec ODT for treating migraine continues to demonstrate strong demand in the United States. Higher operating expense drags down the bottom line.

LLY : 226.40 (-2.28%)
AMGN : 213.11 (-0.23%)
ABBV : 107.72 (+0.61%)
BHVN : 132.88 (-0.37%)
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -16.61% and 0.02%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies...

BHVN : 132.88 (-0.37%)
Biohaven Reports Second Quarter 2021 Financial Results And Recent Business Developments

/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases including...

BHVN : 132.88 (-0.37%)
Analysts Estimate Biohaven Pharmaceutical Holding Company Ltd. (BHVN) to Report a Decline in Earnings: What to Look Out for

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

BHVN : 132.88 (-0.37%)
Biohaven's Nurtec® ODT Signs as Official Migraine Partner of Big Machine Music City Grand Prix Race

/PRNewswire/ -- Biohaven Pharmaceuticals (NYSE:BHVN) announced today Nurtec ODT (rimegepant) is the official migraine partner of the Big Machine Music City Grand Prix. of Rick Ware Racing will pilot...

BHVN : 132.88 (-0.37%)
Biohaven to Report Second Quarter 2021 Financial Results and Recent Business Developments on August 9, 202

/PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological...

BHVN : 132.88 (-0.37%)
Biohaven (BHVN) Q2 Nurtec Preliminary Sales Top Expectations

Biohaven Pharmaceutical's (BHVN) sole approved drug, Nurtec ODT's preliminary sales outperform expectations. Resultantly, share increase 13.6%.

BAYRY : 13.9900 (+2.04%)
RGEN : 307.37 (-4.92%)
BHVN : 132.88 (-0.37%)
BNTX : 307.09 (-7.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which...

See More

Key Turning Points

3rd Resistance Point 139.44
2nd Resistance Point 136.97
1st Resistance Point 134.93
Last Price 132.88
1st Support Level 130.42
2nd Support Level 127.95
3rd Support Level 125.91

See More

52-Week High 139.66
Last Price 132.88
Fibonacci 61.8% 109.80
Fibonacci 50% 100.58
Fibonacci 38.2% 91.36
52-Week Low 61.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar